BUY Akums Drugs and Pharmaceuticals — ICICI Securities, 22 Dec 2025

byICICI SecuritiesHorizon: NA (inferred 1 year)22 Dec 2025via Institutional / Brokerage Research

Entry₹443.15Inferred

Target₹600

Stop lossNot given

Exit₹60011 Jun 2026, 12:06 pm

Target hit+35.39%0.00%upside left

Follow ICICI Securities for new calls(68% target hit, 1025 closed calls)Get alerts Watch AKUMS for new buy/sell callsGet alerts See 3 active Long-term calls on AKUMS See 40 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 8 Sept, 4:02 am IST

2 supporting2 neutral0 opposing

Supports the BUY call (2)

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·11 Jun · today

Akums Drugs and Pharmaceuticals reported Q4 FY26 operating revenue of ₹1,158 crore (up 9.7% YoY) and Adj EBITDA of ₹152 crore (up 61.6% YoY). Full-year FY26 revenue was ₹4,359 crore and Adj EBITDA was

NSE · Press Release·14 May · 4w ago

Neutral / worth noting (2)

Company received assessment order(s) from the Income Tax Department.

BSE · Company Update·20 May · 3w ago

Akums Drugs and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

NSE · Outcome of Board Meeting·14 May · 4w ago

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.